Clinical experience of idarucizumab use in cases of cardiac tamponade under uninterrupted anticoagulation of dabigatran during catheter ablation of atrial fibrillation
Anticoagulants are prescribed for prevention of thromboembolic events (TE) of atrial fibrillation (AF), however, their effects have a negative impact on disastrous bleeding outcomes. Idarucizumab was developed to reverse the anticoagulation effects of dabigatran. This study aimed to retrospectively investigate the clinical efficacy and safety of idarucizumab in the setting of progressive emergent bleeding events associated with catheter ablation (CA). Dabigatran is given uninterruptedly as an anticoagulant in patients undergoing CA of AF. The capacity of idarucizumab to reverse the anticoagulant effects of dabigatran in patients with cardiac tamponade associated with CA was examined by measuring the activated partial thromboplastin time (aPTT), active clotting time (ACT), and prothrombin international normalizing ratio (PT-INR). The primary endpoint was effective hemostasis. This analysis included 21 patients receiving idarucizumab, given for restoration of hemostasis. In all 21 patients, hemostasis was restored at a median of 205.6 ± 14.8 min. Normal intraoperative cessation of bleeding was reported in 16 patients, and completion of hemostasis was also ascertained in the remaining four within 5 h. No TEs occurred within 72 h after the idarucizumab administration. Despite a significant reduction in the aPTT and ACT, no significant change was observed in PT-INR after administering idarucizumab. In emergency situations, idarucizumab was able to reverse dabigatran within a relatively short period without any serious adverse events.
KeywordsIdarucizumab Dabigatran Anticoagulation Atrial fibrillation Antidote
- 8.Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med;361:2342–2352Google Scholar
- 12.Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW et al. on behalf of the RE-LY Investigators (2014) The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients. The RE-LY Trial (randomized evaluation of long-term anticoagulation therapy. J Am Coll Cardiol 63:321–328CrossRefGoogle Scholar
- 22.Glund S, Stangier J, Schmohl M, Gansser D, Norris S, van Ryn J et al. (2015) Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomized, placebo-controlled, double-blind phase 1 trial. Lancet 386:680–690CrossRefGoogle Scholar
- 25.Reilly PA, Lehr T, Haertter S, Connoly SJ, Yusuf S, Eikelboom JW et al. (2014) The effect of dabigatran plasma concentration and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (randomized evaluation of long-term anticoagulation therapy). J Am Coll Cardiol 63:321–328CrossRefGoogle Scholar
- 28.Grottke O, van Ryn J, Sprink HM, Rossaint R (2014) Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model. Crit Care 18:R27. https://doi.org/10.1186/cc13717 CrossRefGoogle Scholar